Bone metabolism changes in patients with inflammatory bowel disease;Alteraciones del metabolismo óseo en los pacientes con enfermedad inflamatoria intestinal

Revista Espanola de Enfermedades Digestivas

Volumn 97, Issue 11, 2005, Pages 815-829

  Legido, J ^a   Gisbert, J P ^a   Pajares, J M ^a   Mate J ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; BUDESONIDE; CALCITONIN; CALCIUM; CORTICOSTEROID; DEOXYPYRIDINOLINE; ESTROGEN; ETIDRONIC ACID; FLUORIDE SODIUM; GLUCOCORTICOID; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; OSTEOCALCIN; PAMIDRONIC ACID; PLACEBO; PREDNISOLONE; RISEDRONIC ACID; SEX HORMONE; TESTOSTERONE; THIAZIDE DIURETIC AGENT; VITAMIN D; VITAMIN K GROUP;

BODY MASS; BONE ATROPHY; BONE DENSITOMETRY; BONE DENSITY; BONE METABOLISM; CALCIUM DEFICIENCY; CLINICAL TRIAL; COLON CROHN DISEASE; CONSTIPATION; CORTICOSTEROID INDUCED OSTEOPOROSIS; CORTICOSTEROID THERAPY; DIARRHEA; DISEASE ACTIVITY; DISEASE DURATION; DRINKING BEHAVIOR; DRUG DOSE REGIMEN; ENTERITIS; ESOPHAGITIS; ESOPHAGUS ULCER; ESTROGEN THERAPY; EXERCISE; GASTROINTESTINAL SURGERY; HEREDITY; HUMAN; IMMOBILIZATION; INFLAMMATION; METABOLIC BONE DISEASE; MUSCULOSKELETAL DIAGNOSIS; MUSCULOSKELETAL SYSTEM EXAMINATION; NAUSEA; OSTEOPENIA; OSTEOPOROSIS; PATHOLOGIC FRACTURE; PATHOPHYSIOLOGY; PEDIATRICS; PREVALENCE; REVIEW; RISK FACTOR; SCREENING TEST; SEX DIFFERENCE; SMOKING; ULCERATIVE COLITIS; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

BONE DENSITY; BONE DISEASES, METABOLIC; CLINICAL TRIALS; HUMANS; INFLAMMATORY BOWEL DISEASES; RISK FACTORS;

EID: 33645326568     PISSN: 11300108     EISSN: 11300108     Source Type: Journal    
DOI: 10.4321/S1130-01082005001100006     Document Type: Review

References (53)

1. Abitbol V, Mary JY, Roux C, Soule JC, Belaiche J, Dupas JL, et al. Osteoporosis in inflammatory bowel disease: effect of calcium and vitamin D with or without fluoride. Aliment Pharmacol Ther 2002; 16: 919-27.
2. Stockbrugger RW, Schoon EJ, Bollani S, Mills PR, Israeli E, Landgraf L, et al. Discordance between the degree of osteopenia and the prevalence of spontaneous vertebral fractures in Crohn's disease. Aliment Pharmacol Ther 2002; 16: 1519-27.
3. Bregenzer N, Erban P, Albrich H, Schmitz G, Feuerbach S, Scholmerich J, et al. Screening for osteoporosis in patients with inflammatory bowel disease by using urinary N-telopeptides. Eur J Gastroenterol Hepatol 2002; 14: 599-605.
4. Klaus J, Armbrecht G, Steinkamp M, Bruckel J, Rieber A, Adler G, et al. High prevalence of osteoporotic vertebral fractures in patients with Crohn's disease. Gut 2002; 51: 654-8.
5. Bernstein CN, Blanchard JF, Leslie W, Wajda A, Yu BN. The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. Ann Intern Med 2000; 133: 795-9.
6. Rosen H. metabolic bone disease in inflammatory bowel disease. Up to date 2000; 8.
7. Silvennoinen JA, Karttunen TJ, Niemela SE, Manelius JJ, Lehtola JK. A controlled study of bone mineral density in patients with inflammatory bowel disease. Gut 1995; 37: 71-6.
8. Compston JE. Review article: osteoporosis, corticosteroids and inflammatory bowel disease. Aliment Pharmacol Ther 1995; 9: 237-50.
9. Schoon EJ, Blok BM, Geerling BJ, Russel MG, Stockbrugger RW, Brummer RJ. Bone mineral density in patients with recently diagnosed inflammatory bowel disease. Gastroenterology 2000; 119: 1203-8.
10. Pollak RD, Karmeli F, Eliakim R, Ackerman Z, Tabb K, Rachmilewitz D. Femoral neck osteopenia in patients with inflammatory bowel disease. Am J Gastroenterol 1998; 93: 1483-90.
11. Bjarnason I, Macpherson A, Mackintosh C, Buxton-Thomas M, Forgacs I, Moniz C. Reduced bone density in patients with inflammatory bowel disease. Gut 1997; 40: 228-33.
12. American Gastroenterological Association medical position statement: guidelines on osteoporosis in gastrointestinal diseases. Gastroenterology 2003; 124: 791-4.
13. Bernstein CN. Treatment of the extraintestinal manifestations of inflammatory bowel disease. Curr Gastroenterol Rep 2002; 4: 513-6.
14. Jahnsen J. Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis: a population based study. Gut 1997; 40: 313-4.
15. Ghosh S. Low bone mineral density Crohn's disease, but not in ulcerative colitis at diagnosis. Gastroenterology 1994; 107: 1031-9.
16. Ardizzone S, Bollani S, Bettica P, Bevilacqua M, Molteni P, Bianchi Porro G. Altered bone metabolism in inflammatory bowel disease: there is a difference between Crohn's disease and ulcerative colitis. J Intern Med 2000; 247: 63-70.
17. Boot AM, Bouquet J, Krenning EP, de Muinck Keizer-Schrama SM. Bone mineral density and nutritional status in children with chronic inflammatory bowel disease. Gut 1998; 42: 188-94.
18. Lamb EJ, Wong T, Smith DJ, Simpson DE, Coakley AJ, Moniz C, et al. Metabolic bone disease is present at diagnosis in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2002; 16: 1895-902.
19. Semeao EJ, Stallings VA, Peck SN, Piccoli DA. Vertebral compression fractures in pediatric patients with Crohn's disease. Gastroenterology 1997; 112: 1710-3.
20. García-Planella E. DE. Osteopenia y osteoporosis en la enfermedad inflamatoria intestinal. Gastroenterol Hepatol 2004; 27: 417-24.
21. Schoon EJ, Geerling BG, Van Dooren IM, Schurgers LJ, Vermeer C, Brummer RJ, et al. Abnormal bone turnover in long-standing Crohn's disease in remission. Aliment Pharmacol Ther 2001; 15: 783-92.
22. Robinson RJ, Iqbal SJ, Al-Azzawi F, Abrams K, Mayberry JF. Sex hormone status and bone metabolism in men with Crohn's disease. Aliment Pharmacol Ther 1998; 12: 21-5.
23. Silvennoinen JA, Lehtola JK, Niemela SE. Smoking is a risk factor for osteoporosis in women with inflammatory bowel disease. Scand J Gastroenterol 1996; 31: 367-71.
24. Silverberg MS. Bone density in inflammatory bowel disease. Clinical perspectives in gastroenterology, 2000.
25. Cohen S. Diagnosis and management of the bone mineral effects of inflammatory bowel disease: Crohn's and Colitis Foundation of America.
26. Robinson RJ, al-Azzawi F, Iqbal SJ, Kryswcki T, Almond L, Abrams K, et al. Osteoporosis and determinants of bone density in patients with Crohn's disease. Dig Dis Sci 1998; 43: 2500-6.
27. von Tirpitz C. Effect of systemic glucocorticoids therapy on bone metabolism and the osteoprotegerina system in patients with active Crohn's disease. Eur J Gastroenterol Hepatol 2003; 15: 1165-70.
28. Habtezion A, Silverberg MS, Parkes R, Mikolainis S, Steinhart AH. Risk factors for low bone density in Crohn's disease. Inflamm Bowel Dis 2002; 8: 87-92.
29. de Jong DJ, Corstens FH, Mannaerts L, van Rossum LG, Naber AH. Corticosteroid-induced osteoporosis: does it occur in patients with Crohn's disease? Am J Gastroenterol 2002; 97: 2011-5.
30. Schulte CM, Dignass AU, Goebell H, Roher HD, Schulte KM. Genetic factors determine extent of bone loss in inflammatory bowel disease. Gastroenterology 2000; 119: 909-20.
31. Lichtenstein GR. Evaluation of bone mineral density in inflammatory bowel disease: current safety focus. Am J Gastroenterol 2003; 98: S24-30.
32. Scott EM, Gaywood I, Scott BB. Guidelines for osteoporosis in coeliac disease and inflammatory bowel disease. British Society of Gastroenterology. Gut 2000; 46 (Supl. 1): i1-8.
33. Robinson RJ, Iqbal SJ, Abrams K, Al-Azzawi F, Mayberry JF. Increased bone resorption in patients with Crohn's disease. Aliment Pharmacol Ther 1998; 12: 699-705.
34. Schoon EJ, Muller MC, Vermeer C, Schurgers LJ, Brummer RJ, Stockbrugger RW. Low serum and bone vitamin K status in patients with longstanding Crohn's disease: another pathogenetic factor of osteoporosis in Crohn's disease? Gut 2001; 48: 473-7.
35. Loftus EV, Jr., Achenbach SJ, Sandborn WJ, Tremaine WJ, Oberg AL, Melton LJ, 3rd. Risk of fracture in ulcerative colitis: a population-based study from Olmsted County, Minnesota. Clin Gastroenterol Hepatol 2003; 1: 465-73.
36. Arden NK, Cooper C. Osteoporosis in patients with inflammatory bowel disease. Gut 2002; 50: 9-10.
37. Card T. Hip fractures in patients with inflammatory bowel disease and their relationship to corticosteroid use: a population based study. Gut 2004; 53: 251-5.
38. Loftus EV, Jr, Crowson CS, Sandborn WJ, Tremaine WJ, O'Fallon WM, Melton LJ, 3rd. Long-term fracture risk in patients with Crohn's disease: a population-based study in Olmsted County, Minnesota. Gastroenterology 2002; 123: 468-75.
39. García-Planella E. Osteoporosis y enfermedad inflamatoria intestinal; 2002.
40. Clements D, Motley RJ, Evans WD, Harries AD, Rhodes J, Coles RJ, et al. Longitudinal study of cortical bone loss in patients with inflammatory bowel disease. Scand J Gastroenterol 1992; 27: 1055-60.
41. Leslie WD. All patients with inflammatory bowel disease should have bone density assessment: con. Inflamm Bowel Dis 2001; 7: 163-7; discussion 168-9.
42. Bernstein CN. Extraintestinal manifestations of inflammatory bowel disease. Curr Gastroenterol Rep 2001; 3: 477-83.
43. Compston JE. Can biochemical markers be used to screen patients with inflammatory bowel disease for osteoporosis? Eur J Gastroenterol Hepatol 2002; 14: 587-9.
44. Papaioannou A, Ferko NC, Adachi JD. All patients with inflammatory bowel disease should have bone density assessment: pro. Inflamm Bowel Dis 2001; 7: 158-62; discussion 168-9.
45. Silvennoinen J, Risteli L, Karttunen T, Risteli J. Increased degradation of type I collagen in patients with inflammatory bowel disease. Gut 1996; 38: 223-8.
46. Ledro Cano D, Torres Dominguez Y, Castro Laria L, Saenz Dana M, Herrerias Esteban JM, Herrerias Gutierrez JM. Biochemical markers and bone densitometry in inflammatory bowel disease. Rev Esp Enferm Dig 2000; 92: 595-600.
47. Bailen LS. Bones and Crohn's: should we treat Crohn's disease patients with alendronate? Inflamm Bowel Dis 2001; 7: 175-6.
48. Vogelsang H, Ferenci P, Resch H, Kiss A, Gangl A. Prevention of bone mineral loss in patients with Crohn's disease by long-term oral vitamin D supplementation. Eur J Gastroenterol Hepatol 1995; 7: 609-14.
49. von Tirpitz C, Klaus J, Bruckel J, Rieber A, Scholer A, Adler G, et al. Increase of bone mineral density with sodium fluoride in patients with Crohn's disease. Eur J Gastroenterol Hepatol 2000; 12: 19-24.
50. Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997; 337: 382-7.
51. Haderslev K. Alendronate increases lumbar spine mineral density in patients with Crohn's disease. Gastroenterol 2000; 119: 639-46.
52. Bartram SA, Peaston RT, Rawlings DJ, Francis RM, Thompson NP. A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease. Aliment Pharmacol Ther 2003; 18: 1121-7.
53. Danes I. ¿Cómo se puede prevenir y tratar la osteoporosis inducida por glucocorticoides? Med Clin (Barc) 2003; 120: 473-5.